Patents by Inventor L. Jeannine Brady

L. Jeannine Brady has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microbial polynucleotides expressed during infection of a host
    Patent number: 8034571
    Abstract: Disclosed are methods for obtaining antigens that are expressed by pathogenic microorganism during an infection process, as well as the antigens so obtained. Also disclosed are isolated polynucleotides encoding said antigens, recombinant polypeptides expressed from the isolated polypeptides, antibodies capable of forming immune complexes with the obtained antigens, and various other compositions useful in the detection, diagnosis, prevention and/or treatment of a microbial infection. The methods of the invention utilize pooled sera from patients who have partly or completely undergone infection by a microbial organism in order to obtain genes that are expressed during in vivo but not during in vitro growth of the microbial organism.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: October 11, 2011
    Assignee: Oragenics, Inc.
    Inventors: Martin Handfield, Ann Progulske-Fox, L. Jeannine Brady, Jeffrey D. Hillman
  • Cloning of non-IgA Fc binding forms of the group B streptococcal beta antigens
    Patent number: 5766606
    Abstract: The subject invention concerns the genetic manipulation of the gene encoding a group B streptococcal (GBS) surface protein known as the beta antigen. The beta antigen is known to bind to the Fc region of IgA immunoglobulins in a non-immune manner. The portion of beta antigen gene which encodes the IgA binding function has been identified and removed using genetic engineering techniques. The novel polypeptide encoded by the altered beta antigen gene does not bind to IgA but does immunoreact with monospecific anti-beta antigen antisera raised against the wild-type beta antigen protein. This non-IgA binding form of the beta antigen may be used as a component in a human vaccine to protect against GBS infections.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: June 16, 1998
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: L. Jeannine Brady
  • Gamma antigen of pathogenic group B streptococci
    Patent number: 5721339
    Abstract: The subject invention concerns a novel in vitro process for identifying and quantifying native antigens on potentially pathogenic group B streptococci bacteria present in a clinical specimen. The invention process is made possible by the discovery of novel bacterial markers denoted .gamma. and .delta. epitopes which are expressed by a variety of group B streptococcal strains.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 24, 1998
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Michael D. P. Boyle, L. Jeannine Brady
  • Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
    Patent number: 5595740
    Abstract: The subject invention concerns the genetic manipulation of the gene encoding a group B streptococcal (GBS) surface protein known as the beta antigen. The beta antigen is known to bind to the Fc region of IgA immunoglobulins in a non-immune manner. The portion of beta antigen gene which encodes the IgA binding function has been identified and removed using genetic engineering techniques. The novel polypeptide encoded by the altered beta antigen gene does not bind to IgA but does immunoreact with monospecific anti-beta antigen antisera raised against the wild-type beta antigen protein. This non-IgA binding form of the beta antigen may be used as a component in a human vaccine to protect against GBS infections.
    Type: Grant
    Filed: May 16, 1994
    Date of Patent: January 21, 1997
    Assignee: University of Florida
    Inventor: L. Jeannine Brady
  • Antigen of group B streptococci
    Patent number: 5472696
    Abstract: The subject invention concerns a novel in vitro process for identifying and quantifying native antigens on potentially pathogenic group B streptococci bacteria present in a clinical specimen. The invention process is made possible by the discovery of novel bacterial markers denoted .gamma. and .delta. epitopes which are expressed by a variety of group B streptococcal strains.
    Type: Grant
    Filed: June 14, 1994
    Date of Patent: December 5, 1995
    Assignee: Univ. of Florida Research Foundation, Inc.
    Inventors: Michael D. P. Boyle, L. Jeannine Brady